Evidence map›Paper›PMID 25325302›Full record

Trial reportBlood cancer journal2014

Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group.

F Hayakawa, T Sakura, T Yujiri, E Kondo, K Fujimaki, O Sasaki, J Miyatake, H Handa, Y Ueda, Y Aoyama and 14 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 3 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 18 institutions in 1 country.

F HayakawaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
T SakuraLeukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
T YujiriThird Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Japan.
E KondoDepartment of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
K FujimakiDepartment of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan.
O SasakiDepartment of Internal Medicine, Miyagi Cancer Center, Natori, Japan.
J MiyatakeDepartment of Hematology and Rheumatology, Kinki University Faculty of Medicine, Osaka-sayama, Japan.
H HandaDepartment of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
Y UedaDepartment of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
Y AoyamaDepartment of Internal Medicine, Seichoukai Fuchu Hospital, Izumi, Japan.
S TakadaLeukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
Y TanakaThird Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Japan.
N UsuiThe Jikei University School of Medicine, Tokyo, Japan.
S MiyawakiDivision of Hematology, Tokyo Metropolitan Otsuka Hospital, Tokyo, Japan.
S SuenobuDepartment of Pediatrics and Child Neurology, Oita University Faculty of Medicine, Oita, Japan.
K HoribeClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
H KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
K OhnishiOncology Center, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Y MiyazakiDepartment of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
S OhtakeDepartment of Clinical Laboratory Science, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Y KobayashiDepartment of Hematology and Oncology, National Cancer Center Hospital, National Cancer Center, Tokyo, Japan.
K MatsuoDepartment of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan.
T NaoeNational Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Japan Adult Leukemia Study Group (JALSG)
Gunma Saiseikai Maebashi Hospital · JPNagoya University · JPNational Hospital Organization · JPYamaguchi University · JPFuchu Hospital · JPFujisawa City Hospital · JPGunma University · JPHamamatsu University School of Medicine · JPJikei University School of Medicine · JPKanazawa University · JPKindai University · JPKurashiki Central Hospital · JPKyushu University · JPMiyagi Prefectural Hospital Organization · JPNagasaki University · JPOita University · JPOkayama University · JPTokyo Metropolitan Ohtsuka Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The superiority of the pediatric protocol for adolescents with acute lymphoblastic leukemia (ALL) has already been demonstrated, however, its efficacy in young adults remains unclear. The ALL202-U protocol was conducted to examine the efficacy and feasibility of a pediatric protocol in adolescents and young adults (AYAs) with BCR-ABL-negative ALL. Patients aged 15-24 years (n=139) were treated with the same protocol used for pediatric B-ALL. The primary objective of this study was to assess the disease-free survival (DFS) rate and its secondary aims were to assess toxicity, the complete remission (CR) rate and the overall survival (OS) rate. The CR rate was 94%. The 5-year DFS and OS rates were 67% (95% confidence interval (CI) 58-75%) and 73% (95% CI 64-80%), respectively. Severe adverse events were observed at a frequency that was similar to or lower than that in children treated with the same protocol. Only insufficient maintenance therapy significantly worsened the DFS (hazard ratio 5.60, P<0.001). These results indicate that this protocol may be a feasible and highly effective treatment for AYA with BCR-ABL-negative ALL.

Indexed as

AdolescentAdultAge FactorsAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalFemaleHumansJapanMalePrecursor Cell Lymphoblastic Leukemia-LymphomaProspective StudiesRemission InductionSurvival RateYoung Adult

Identifiers

PMID25325302
PMCPMC4220650
OpenAlexW1978302657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.